期刊
JOURNAL OF CLINICAL MEDICINE
卷 12, 期 22, 页码 -出版社
MDPI
DOI: 10.3390/jcm12226961
关键词
chronic inflammatory demyelinating polyneuropathy; therapy; immunoglobulin; intravenous; subcutaneous
The therapeutic administration of subcutaneous immunoglobulin (SCIg) offers various advantages over intravenous immunoglobulin (IVIg) in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). SCIg is as effective as IVIg but better tolerated and easier to administer. It is also more convenient and cost-effective, allowing for flexible treatment scheduling at home and improving patients' overall quality of life.
The therapeutic administration of subcutaneous immunoglobulin (SCIg) offers various advantages over intravenous immunoglobulin (IVIg). This narrative review examines and compares SCIg versus IVIg in chronic inflammatory demyelinating polyneuropathy (CIDP). SCIg is as effective as IVIg but is better tolerated and easier to administer, as intravenous access is not required. Furthermore, SCIg administration is more convenient and cost-effective than IVIg, enabling flexible treatment scheduling at home and improving patients' overall quality of life. The availability of highly concentrated immunoglobulin G (IgG) subcutaneous solutions, such as IgPro20, a 20% IgG solution stabilized with L-proline, allows for the administration of larger volumes in a single session, while the parallel development of new technological devices enables the delivery of higher doses over a shorter time. Based on the results of the PATH study, SCIg has become a well-established therapy in CIDP. In addition to discussing the advantages of SCIg, this review summarizes the evolution of SCIg by discussing all the relevant clinical studies which have considered its use in the treatment of CIDP.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据